Positioning CAR T Therapy in Marginal Zone Lymphoma: Efficacy, Safety, and Comparative Insights

Panelists discuss how CAR T therapy is increasingly recognized as a valuable addition to the treatment landscape for marginal zone lymphoma. Compared with conventional therapies, CAR T offers deeper and more durable responses for patients whose disease has returned or resisted prior treatments. The ability to harness a patient’s own immune system for long-term disease control represents a paradigm shift in care.

Comparative data suggest that CAR T therapy delivers strong efficacy while maintaining an acceptable safety profile when administered in experienced centers. By refining patient selection and supportive care, clinicians can maximize benefit while minimizing risk.